C

CSPC Pharmaceutical Group Ltd
HKEX:1093

Watchlist Manager
CSPC Pharmaceutical Group Ltd
HKEX:1093
Watchlist
Price: 4.8 HKD -0.21% Market Closed
Market Cap: 56.1B HKD
Have any thoughts about
CSPC Pharmaceutical Group Ltd?
Write Note

CSPC Pharmaceutical Group Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CSPC Pharmaceutical Group Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Total Current Assets
ÂĄ26.5B
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
18%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Current Assets
ÂĄ28.9B
CAGR 3-Years
19%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Current Assets
ÂĄ15.1B
CAGR 3-Years
15%
CAGR 5-Years
17%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Current Assets
ÂĄ34.8B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
18%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Current Assets
ÂĄ36.4B
CAGR 3-Years
-8%
CAGR 5-Years
-3%
CAGR 10-Years
11%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Current Assets
ÂĄ775.8m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CSPC Pharmaceutical Group Ltd
Glance View

Market Cap
57.1B HKD
Industry
Pharmaceuticals

CSPC Pharmaceutical Group Ltd., a prominent player in the pharmaceutical industry, has charted a strategic path focused on innovation and a diversified portfolio. The company, with its roots in China, has emerged as a formidable force by blending traditional pharmaceutical manufacturing with a strong emphasis on research and development. CSPC's journey is characterized by a commitment to developing high-quality generic drugs, innovative therapeutics, and nutritional products. The company's core business revolves around the production and sale of a wide range of pharmaceuticals, including cardiovascular drugs, oncology treatments, and central nervous system therapies. By leveraging advanced technology and robust research initiatives, CSPC consistently delivers solutions that address both common and complex healthcare needs across the globe. With a strategic focus on both domestic and international markets, CSPC Pharmaceutical Group capitalizes on its extensive distribution network to maximize reach and impact. The company has made significant investments in its production capabilities to maintain stringent quality standards while achieving cost efficiency. Furthermore, CSPC's earnings are bolstered by its expanding pipeline of innovative drugs, developed in-house and through strategic collaborations, which aims to capture emerging therapeutic areas. Overall, CSPC's blend of traditional pharmaceutical expertise, a focus on innovation, and strategic market positioning enables it to maintain a strong operational foothold and to consistently drive revenue growth in an ever-evolving industry landscape.

Intrinsic Value
7.28 HKD
Undervaluation 34%
Intrinsic Value
Price
C

See Also

What is CSPC Pharmaceutical Group Ltd's Total Current Assets?
Total Current Assets
26.5B CNY

Based on the financial report for Sep 30, 2024, CSPC Pharmaceutical Group Ltd's Total Current Assets amounts to 26.5B CNY.

What is CSPC Pharmaceutical Group Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
18%

Over the last year, the Total Current Assets growth was 9%. The average annual Total Current Assets growth rates for CSPC Pharmaceutical Group Ltd have been 11% over the past three years , 15% over the past five years , and 18% over the past ten years .

Back to Top